Eli Lilly and Company / LLY

Equity | Generated Oct 30, 2026 11:31 PM EDT

Current price	Daily move	Bid / Ask	Previous close
$1,414.51	+40.81 +2.97%	-/-	$1,373.70

Market	**NYSE**
Industry	**Pharmaceuticals**
Market data as of	**Oct 30, 2026 11:31 PM EDT**

JW Intelligence Report

Complete | 3 of 3 sections | Oct 30, 2026 6:50 PM EDT

JW Rank	Rank label	Confidence	IV percentile
67.3 / 100	Constructive	high	20 / 100

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,405.00	$1,490.00	$1,362.00	55 / 100

Options stance	**bullish**
Tail-risk safety	**56 / 100**
JW Rank data coverage / as of	**100.0% | Oct 30, 2026 6:50 PM EDT**

Key insight

Lilly Soars After Beating Q3 Expectations, Driving Option Buying

Market read

Eli Lilly (LLY) stock surged over 4% on October 30th after exceeding third-quarter earnings expectations. Strong revenue growth driven by Mounjaro and Zepbound, coupled with a raised full-year revenue guidance, fueled the rally. The company also announced positive results from a diabetes trial for its retatrutide drug candidate. This bullish news flow is reflected in the option market, with elevated implied volatility and strong call buying activity.

Strategy context

The recent earnings beat and positive news flow suggest continued upside potential for LLY. However, investors should be aware of potential profit-taking after the sharp rally.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bullish**
AI analysis updated	**Oct 30, 2026 9:58 AM EDT**

Short-term scenario

Do not chase the open spike. Prefer a 1-3 week tactical long only on a pullback toward the Oct 29 breakout zone. Momentum is strong, but the stock is extended and short-term follow-through is uncertain; this is a trade plan, not advice.

Three-month outlook

Constructive on fundamentals, not a straight line. Leadership in obesity and diabetes, a third 2026 sales raise, Medicare access, and a pipeline catalyst in retatrutide support a grind toward recently lifted Street targets in the mid-$1,500s to mid-$1,600s if volume keeps offsetting price. Uncertainty is high: the stock is overbought after two strong sessions, Q3 included about $900M of benefits management said will not repeat, adjusted EPS guidance was reduced on deal charges, Foundayo missed, China reimbursement already pressured realized prices, and competition plus broader GLP-1 pricing can reassert. An 8-15% consolidation back toward the $1,330-$1,370 area would not, by itself, break the fundamental case. Consensus averages still below the live price partly reflect stale targets, so headline 'upside to consensus' is not a reliable signal until models are fully updated.

Market sentiment

Near-term X tone is bullish and somewhat FOMO-driven after the beat-and-raise, not a broad measured debate. Posts highlight the gap higher, call the GLP-1 franchise a volume story (Mounjaro +65%, Zepbound +49%, guidance up $5.5B), and note buy-side support such as UBS maintaining Buy with a $1,625 target. Options commentary showed profitable call exposure. Counter-sentiment is mostly regret at missing lower entries and residual valuation skepticism, not a rejection of the quarter. Sample size is small and engagement is thin, so this is a weak, noisy signal. Uncertainty: social posts can lag or amplify the open and are not a forecast.

Supporting evidence

LLY stock jumped over 4% on October 30th following Q3 earnings release. | Strong revenue growth was driven by Mounjaro (+65%) and Zepbound (+49%). | Full-year revenue guidance was raised, exceeding analyst expectations. | Positive results from a diabetes trial for retatrutide drug candidate. | Elevated implied volatility and strong call buying activity observed in the options market.

Risk watch

Potential for profit-taking after the significant price increase. | Uncertainty surrounding the durability of volume growth and pricing pressures.

Enhanced price structure

45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor

Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
strong_bull	Above MVWAP	Above 200D trend	medium

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**STRONG BULL | overbought | MACD accelerating**
Trend signal	**STRONG BULL**
RSI signal	**overbought**
RSI (7 / 14 / 21)	**85.42 / 77.88 / 72.86**
RSI velocity	**4.81**
MACD line / signal / histogram	**47.32 / - / 32.10**
MACD acceleration	**5.19**
Stochastic K / D	**85.23 / 82.16**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Above institutional MVWAP | Accumulation bias**
Institutional flow	**14.58**
20-day MVWAP	**$1,264.17**
Price vs 20-day MVWAP	**+11.89%**
Daily reference VWAP	**$1,425.19**
Price vs daily reference	**-0.75%**
Volume	**2.44M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Positive macro velocity**
Macro velocity	**10.50**
20-day / 200-day SMA	**$1,246.01 / $1,091.24**
Bollinger range	**$1,100.71 - $1,391.31**
Bollinger position	**1.090**

Options and volatility intelligence

Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
23 / 100	**22 / 100**	**121.93**	**151.03**

Market regime	**Calm**
Tail-risk regime	**NORMAL TAIL RISK**
Term structure	**backwardation**
Term slope	**-2.33 pts**
Skew read	**balanced**
Liquidity / quote coverage	**100.0%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Oct 30, 2026 2:52 PM EDT**
Options data quality	**Coverage 100.0%**

Option term structure

ATM implied-volatility curve by days to expiration



EXPIRATION	DTE	ATM IV	STATE
2026-11-06	7	37.0%	-
2026-11-13	14	33.4%	-
2026-11-20	21	34.6%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bull Put Spread reference

Short $1,375.00 | Long $1,370.00 | Width $5.00 | Net credit $1.32



Max profit $132.00 | Max loss -$368.00 | Break-even $1,373.68 | Per contract at expiry

Bear Call Spread reference

Short $1,475.00 | Long $1,480.00 | Width $5.00 | Net credit $0.95



Max profit $95.00 | Max loss -$405.00 | Break-even $1,475.95 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-10-29**
Earnings IV-crush risk	**elevated**
Event IV premium	**3.53**
VIX	**22.61**
VVIX	**121.93**
SKEW index	**151.03**
Observation confidence	**high**
Option quote quality	**reliable**

Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts observed	**114**
Contracts with quotes	**114**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

Eli Lilly (LLY) stock surged over 4% on October 30th after exceeding third-quarter earnings expectations. Strong revenue growth driven by Mounjaro and Zepbound, coupled with a raised full-year revenue guidance, fueled the rally. The company also announced positive results from a diabetes trial for its retatrutide drug candidate. This bullish news flow is reflected in the option market, with elevated implied volatility and strong call buying activity.

Options context

Lilly Soars After Beating Q3 Expectations, Driving Option Buying

Wheel context

The recent earnings beat and positive news flow suggest continued upside potential for LLY. However, investors should be aware of potential profit-taking after the sharp rally.

Observed evidence

LLY stock jumped over 4% on October 30th following Q3 earnings release. | Strong revenue growth was driven by Mounjaro (+65%) and Zepbound (+49%). | Full-year revenue guidance was raised, exceeding analyst expectations. | Positive results from a diabetes trial for retatrutide drug candidate. | Elevated implied volatility and strong call buying activity observed in the options market.

Principal risks to monitor

Potential for profit-taking after the significant price increase. | Uncertainty surrounding the durability of volume growth and pricing pressures.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
$1.29T	**48.81**
ROE	Revenue growth
92.6%	**31.7%**
EPS growth	Operating margin
49.3%	**42.2%**
Net profit margin	Gross margin
33.5%	**-**
Free cash flow CAGR	Debt / equity
5.9%	**1.60**
Dividend yield	Beta
0.8%	**0.42**

52-week range

$809.63 - $1,321.21

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Company	**NYSE**
Industry	Country
Pharmaceuticals	**US**
Currency	IPO date
USD	**1970-07-09**
Shares outstanding	52-week return
941.36M	**57.1%**
Book value per share	Revenue per share
$35.98	**$89.14**

Website	lilly.com

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Oct 30, 2026 10:42 AM EDT

Covered Call | 2026-11-06

At signal $1,426.48 | Current $1,414.51

SHORT **Option $1,400.00 B $43.85 / A $48.90**

Conservative | CR $46.38

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$44.91**
ATR as % of price	**3.2%**
Volatility environment	**medium**
Current IV	**31.6%**
IV rank	**21 / 100**
IV percentile	**20 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Oct 30, 2026 7:31 PM EDT**

Technical health and risk radar

Derived indicator health and event context

Overall health	**68 / 100**
Trend health	**92 / 100**
Momentum health	**59 / 100**
Volatility health	**62 / 100**
Structure health	**41 / 100**
Earnings risk / date	**unknown | 2026-10-29**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**high**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,246.01 / $1,197.14 / $1,091.24**
EMA (9 / 21)	**$1,315.31 / $1,263.50**
Bollinger upper / middle / lower	**$1,391.31 / $1,246.01 / $1,100.71**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**1.090**
True high / low	**$1,449.68 / $1,373.70**
5-day true high / low	**$1,449.68 / $1,260.34**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	10.496	**-**
SMA50	2.194	**-**
MVWAP20	14.581	**-**
MACD	5.186	**-**
RSI	4.808	**-**
Volume	531108.670	**-**
ATR	2.850	**-**
T1	-	**38.96 / 1244.03 / 1408.38 / 1288.30**
T2	-	**32.19 / 1226.45 / 1299.43 / 1260.34**
T3	-	**31.77 / 1220.43 / 1297.92 / 1272.07**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,420.90**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Oct 30, 2026 2:52 PM EDT**
Options data coverage	**100.0%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX FLAT**
Front expiration / DTE	**2026-11-06 | 7 DTE**
Front at-the-money IV	**37.0%**
25-delta skew	**2.52**
Put / Call 25-delta	**$1,375.00 Delta -0.256 / $1,475.00 Delta 0.242**
Median option bid/ask spread	**19.7%**
Bid/ask spread	**-**
Contracts observed / quoted	**114 / 114**

Price context

Last Price: 1,420.90 | Bid: 1,420.86 | Ask: 1,421.97 | Previous Close: 1,373.70 | Change: 47.20 | Daily change: 3.44% | Update Time: 2026-10-30T14:52:48.284751-04:00 | Latest History Date: 2026-10-30 | Latest History Price: 1,420.90

Historical context

Trading-day sample: 60 sessions | First Date: 2026-08-07 | Latest Date: 2026-10-30 | Latest Price: 1,420.90 | Max Drawdown 60d Percent: -12.86%

Fundamental context

Current Iv Percent: 31.91% | Iv Rank: 22.83 | Iv Percentile: 22.31 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-11-12

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Oct 30, 2026 11:31 PM EDT. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**